Cite
HARVARD Citation
Campani, C. et al. (2023). Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab. Liver international. pp. 708-717. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Campani, C. et al. (2023). Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab. Liver international. pp. 708-717. [Online].